Pramod Kumar Srivastava (born 15 August 1955) is an American immunologist and physician serving as the Eversource Energy chairman in experimental oncology at the University of Connecticut School of Medicine.
[2][3] Srivastava completed his Ph.D. at the Centre for Cellular and Molecular Biology, Hyderabad, India, and his MD from the University of Connecticut School of Medicine.
[2][4][5] Srivastava was appointed Assistant Professor in the Department of Pharmacology, Mount Sinai School of Medicine, in 1989.
Since 2011, he has been the director of the Carole and Neag Comprehensive Cancer Center at the University of Connecticut School of Medicine.
In addition, Srivastava investigated neuroimmunology interactions and showed how the sympathetic nervous system is critical for the normal development of neutrophils and that dysregulation of this pathway leads to the generation of the immune suppressive myeloid-derived suppressor cells, which promotes the proliferation of regulatory T cells.